nih.
"Life threatening infections are a growing concern globally ," says Dr.S.
Actual results may vary materially from the forward-looking statements.

yersinia vibrio

The antibodies will be produced under
Good Manufacturing Practices (cGMP) at XOMA's manufacturing facility. Department of Health and Human Services., The U.V. Antibiotic resistance costs U. In fact, development and approvals
of new antibacterial agents have decreased by 56 percent over the past 20
years (1998-2002 vs . constellatus), Bacteroides
fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides
vulgatus, Clostridium perfringens, and Peptostreptococcus micros.

pinworms clostridium

S. The company pipeline includes products from collaborative
product development programs with Chiron Corporation, Millennium
Pharmaceuticals , Inc.S. in the near future. The
safety and effectiveness of TYGACIL in patients below age 18 and lactating
women have not been established.
For a copy of TYGACIL Prescribing Information, please visit
http://www. The
Company assumes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or
otherwise.

noroviruses cyclosporiasis

citizens from the harmful effects of biological agents
used as instruments of terror. SRI's Biosciences Division works with
government agencies and commercial pharmaceutical and biotechnology
companies to provide a broad range of preclinical drug discovery and
development services, including medicinal chemistry , custom synthesis,
regulatory support, efficacy and safety evaluations, pharmacokinetics
and metabolism studies, analytical chemistry and formulation design in
production in GLP and cGMP environments.

The Australian Therapeutic Goods Administration and the South
African Medicines Control Council (MCC) granted priority evaluation to
TYGACIL.S.
TYGACIL may cause fetal harm when administered to a pregnant woman.

spoilage noroviruses

HHSN266200500004C. For more information
about XOMA's product pipeline and antibody product development
capabilities and technologies, please visit XOMA's website at
http: //www.

A Clinical Challenge
The U. According to the CDC, antibiotic
resistance has become so widespread that many significant bacterial infections
in the world are becoming resistant to commonly used antibiotics.5 percent) and vomiting (19.

There is also information about poisonings from toxic animals and plants.

staphylococcal cyclosporiasis

government to develop new
therapies to counter these biological threats.xoma. These risks, including those
related to the results of pre-clinical testing, the timing or results
of pending and future clinical trials (including the design and
progress of clinical trials; safety and efficacy of the products being
tested; action, inaction or delay by the FDA, European or other
regulators or their advisory bodies; and analysis or interpretation
by, or submission to, these entities or others of scientific data),
changes in the status of the existing collaborative relationships, the
ability of collaborators and other partners to meet their obligations,
market demand for products, scale up and marketing capabilities,
competition, uncertainties regarding the status of biotechnology
patents, uncertainties as to the cost of protecting intellectual
property and risks associated with XOMA's status as a Bermuda company,
are described in more detail in the Company's most recent annual
report on Form 10-K and in other SEC filings. The overall
discontinuation rate for TYGACIL (5.

flukes poisoning

"Numerous events in the United States over the past few years
serve as a stark reminder that the use of biological agents remains a
real threat," said John L. Actual results could differ
materially from those anticipated due to certain risks inherent in the
biotechnology industry and for companies engaged in the development of
new products in a regulated market. Food and Drug
Administration (FDA) today approved Tygacil(TM) (tigecycline), a novel I. Antibiotic development has slowed to the point that FDA has had
few opportunities to approve new agents. New classes of antibiotics are needed to
address increasing antibiotic resistance among common pathogens. intermedius , and S. The Company's major divisions
include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge
Animal Health.

poisoning caliciviruses

S. News releases, fact sheets and other
NIAID-related materials are available on the NIAID Web site at
http://www.J. Wyeth anticipates that TYGACIL will be available to hospitals in the
U.

Important Safety Information
TYGACIL is contraindicated in patients with known hypersensitivity to
tigecycline. It is a leader in the
discovery, development , manufacturing, and marketing of pharmaceuticals,
vaccines, biotechnology products and nonprescription medicines that improve
the quality of life for people worldwide.

clostridium spoilage

"Bacterial infections are becoming more difficult to treat,
with resistant strains on the increase.

salmonellosis tapeworms

"As an industry leader in developing monoclonal antibodies, XOMA
is committed to working with the U. NIAID
supports basic and applied research to prevent, diagnose and treat
infectious diseases such as HIV/AIDS and other sexually transmitted
infections, influenza, tuberculosis, malaria and illness from
potential agents of bioterrorism . These statements are based on
assumptions that may not prove accurate.

FDA APPROVES TYGACIL(TM) FIRST-IN-CLASS ANTIBIOTIC

TYGACIL is approved for adults with complicated skin and skin structure
infections (cSSSI) caused by Escherichia coli, Enterococcus faecalis
(vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-
susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus
anginosus grp.
TYGACIL is also approved for adults with complicated intra-abdominal
infections (cIAI) caused by Citrobacter freundii, Enterobacter cloacae,
Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus
faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus
(methicillin-susceptible isolates only), Streptococcus anginosus grp .7 percent).

For information about pathogens transmitted in water or food.

staphylococcal yersinia

S.com) is one of the
world 's leading independent research and technology development
organizations. Founded as Stanford Research Institute in 1946, SRI has
been meeting the strategic needs of clients for almost 60 years.

yersinia salmonellosis

TYGACIL is indicated for the treatment of complicated intra-
abdominal infections (cIAI) and complicated skin and skin structure infections
(cSSSI) in adults.com

About Wyeth
Wyeth (NYSE: WYE) is one of the world's largest research-driven
pharmaceutical and health care products companies .

The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events that
involve risks and uncertainties including , without limitation, risks
associated with the inherent uncertainty of the timing and success of
pharmaceutical research, product development, manufacturing,
commercialization, economic conditions including interest and currency
exchange rate fluctuations, changes in generally accepted accounting
principles, the impact of competitive or generic products, trade-buying
patterns, wars or terrorist acts, product liability and other types of
lawsuits, the impact of legislation and regulatory compliance and obtaining
reimbursement, favorable drug pricing, access and other approvals,
environmental liabilities, and patent, and other risks and uncertainties,
including those detailed from time to time in the Company's periodic reports,
including current reports on Form 8-K, quarterly reports on Form 10-Q and the
annual report on Form 10-K, filed with the Securities and Exchange Commission .

staphylococcus clostridium

Under the 18-month contract, XOMA will develop monoclonal antibody
therapeutics using proprietary antibody expression systems to produce
anti-type A-botulinum neurotoxin monoclonal antibodies including a
Master Cell Bank (MCB), Manufacturer's Working Cell Bank (MWCB) and
other designated deliverables . Castello, president, chairman and CEO of
XOMA. TYGACIL provides clinicians with a novel,
broad -spectrum option that can be used at the onset of treatment when the
specific bacteria present are not yet known.
In clinical trials, empiric monotherapy with TYGACIL provided comparable
clinical cures rates in cSSSI to vancomycin and aztreonam, a combination
treatment.

caliciviruses poisoning

"
"We have previously stated that an important part of our strategy
for achieving profitability is increased utilization of our process
development and manufacturing assets," continued Castello.4 percent).

rwis gastroenteritis

"
TYGACIL can be used as an empiric monotherapy to treat a variety of cIAI
and cSSSI, both hospital- and community -acquired, including complicated
appendicitis, infected burns, intra-abdominal abscesses, deep soft tissue
infections, and infected ulcers. The increasing
prevalence of resistant bacteria often necessitates the use of combinations of
antibiotics to fight infections. intermedius, and S.
(includes S. Use of TYGACIL during tooth development may
cause permanent discoloration of the teeth .

flukes staphylococcus

niaid. Centers for Disease Control and Prevention (CDC) states that
persons infected with drug-resistant organisms are more likely to have longer
hospital stays and require treatment with multiple drugs . TYGACIL was accepted by the European Medicines
Agency (EMEA) for review, and Wyeth has filed for approval in other countries,
including Brazil, Canada, Colombia, Mexico, Switzerland, Taiwan, and
Venezuela.

safefood cryptosporidiosis

Botulinum neurotoxins are one of these
biological threats and new vaccines, therapies and diagnostics are
needed to counter the potential terrorist use of these toxins.sri.
antibiotic with a broad spectrum of antimicrobial activity, including activity
against the drug-resistant bacteria methicillin-resistant Staphylococcus
aureus (MRSA).

About TYGACIL
TYGACIL, the first antibiotic approved in a new class called
glycylcyclines, was developed by Wyeth to overcome key mechanisms of
resistance that have affected antibiotic use.
Wyeth now awaits decisions on approval of TYGACIL from other regulatory
bodies around the world. Pseudomembranous colitis has been
reported with nearly all antibacterial agents and may range from mild to life
threatening .

noroviruses schistosomiasis

About XOMA

XOMA develops and commercializes antibody and other protein-based
biopharmaceuticals for cancer, immune disorders and infectious
diseases. society
between $4 billion and $5 billion annually.

trichinosis staphylococcal

XOMA Awarded $15 Million Contract from NIAID to Help Fight Bioterrorism; XOMA to Develop Three Anti-Botulinum Neurotoxin Monoclonal Antibodies

----XOMA Ltd.
This project will be 100% funded with Federal funds from NIAID under
Contract No.gov

About SRI

Silicon Valley-based SRI International (www. The division specializes in
cancer, infectious disease and neurobiological research. Provides Physicians With Treatment Alternative
for Complicated Skin and Intra-abdominal Infections

MADISON, N. 1983-1987). Empiric monotherapy with TYGACIL also provided clinical cure rates
comparable to imipenem/cilastatin, an empiric treatment for cIAI .0 percent) was comparable to vancomycin
and aztreonam (5.

schistosomiasis flukes

About NIAID

NIAID is a component of the National Institutes of Health, an
agency of the U.S.com/

Certain statements contained herein concerning current
collaborations and product development or that otherwise relate to
future periods, are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. The approval of TYGACIL will provide
physicians with an important option for patients with complicated skin, skin
structure, and intra -abdominal infections. TYGACIL should be administered with caution in patients with
known hypersensitivity to, and may have adverse effects similar to,
tetracycline class antibiotics.

salmonellosis sood

In addition, TYGACIL does not
require dosage adjustment in patients with impaired renal function, and is
conveniently dosed every 12 hours.

campylobacteriosis rotavirus

Business Editors/Health/Medical Writers
BIOWIRE2K

BERKELEY, Calif . citizens against the harmful effects of biological
agents used in bioterrorism. SRI International , an independent,
nonprofit research institute based in Menlo Park, CA, will be a
subcontractor under this contract and will develop potency assays to
support antibody characterization."

About Botulism Neurotoxin (BoNT)

With the recent deliberate exposure of postal workers, other
government employees, and the American public to Bacillus anthracis
spores, there is an urgent need to devise effective measures to
protect U. The
nonprofit research institute performs client-sponsored research and
development for government agencies, commercial businesses and
nonprofit foundations.S.
Additionally, few broad-spectrum antibiotic agents are currently in
development.

trichinosis staphylococcus

, and Aphton Corporation .
Joseph Camardo, Senior Vice President, Global Medical Affairs, Wyeth
Pharmaceuticals. constellatus ),
Streptococcus pyogenes, and Bacteroides fragilis. The submission also included in vitro data
showing activity against both gram-negative and gram-positive bacteria,
anaerobes, and certain drug-resistant pathogens. In clinical trials, the most common
treatment-emergent adverse events in patients treated with TYGACIL were nausea
(29.

campylobacteriosis cyclosporiasis

"This
contract with NIAID is an important step forward in achieving this
objective. (includes S. anginosus, S. anginosus, S.
The TYGACIL New Drug Application (NDA) submission included data from four
pivotal phase III studies examining the safety and efficacy of TYGACIL for the
treatment of cIAI and cSSSI. Monotherapy should be used with caution in patients with
clinically apparent intestinal perforation.

pinworms trichinosis

(Nasdaq:XOMA) today announced that it was awarded a $15 million
contract from the National Institute of Allergy and Infectious
Diseases (NIAID) , a part of the National Institutes of Health (NIH),
to produce three botulinum neurotoxin monoclonal antibodies designed
to protect U. NIAID also supports research on
transplantation and immune-related illnesses, including autoimmune
disorders, asthma and allergies. Approval of this first-in-class product comes at a time
when the need for new antibiotic options to combat serious, resistant
infections is increasing.3 percent) and imipenem/cilastatin (4.wyeth.

Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has leading
products in the areas of women's health care, cardiovascular disease, central
nervous system, inflammation, transplantation, hemophilia, oncology, vaccines
and nutritional products.

cryptosporidiosis noroviruses